29.12
-0.58(-1.95%)
Currency In USD
| Previous Close | 29.7 |
| Open | 29.57 |
| Day High | 29.81 |
| Day Low | 28.94 |
| 52-Week High | 60.37 |
| 52-Week Low | 25.81 |
| Volume | 1.24M |
| Average Volume | 1.92M |
| Market Cap | 2.81B |
| PE | -5.31 |
| EPS | -5.48 |
| Moving Average 50 Days | 32.34 |
| Moving Average 200 Days | 39.15 |
| Change | -0.58 |
If you invested $1000 in Ultragenyx Pharmaceutical Inc. (RARE) 10 years ago, it would be worth $269.36 as of August 20, 2025 at a share price of $29.12. Whereas If you bought $1000 worth of Ultragenyx Pharmaceutical Inc. (RARE) shares 5 years ago, it would be worth $331.06 as of August 20, 2025 at a share price of $29.12.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
Ultragenyx Initiates Rolling Submission of Biologics License Application (BLA) to U.S. FDA for DTX401 AAV Gene Therapy for the Treatment of Glycogen Storage Disease Type Ia (GSDIa)
GlobeNewswire Inc.
Aug 18, 2025 12:00 PM GMT
Company expects to complete BLA submission in the fourth quarter of 2025NOVATO, Calif., Aug. 18, 2025 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE) today announced the initiation of a rolling submission of a Biologics License Ap
Ultragenyx Completes Enrollment of Phase 3 Aspire Study Evaluating GTX-102 for the Treatment of Angelman Syndrome
GlobeNewswire Inc.
Jul 31, 2025 8:05 PM GMT
Company expects to complete Phase 3 Aspire study in the second half of 2026 Aurora study of GTX-102 in additional ages and genotypes on track to initiate in the second half of 2025 NOVATO, Calif., July 31, 2025 (GLOBE NEWSWIRE) -- Ultragenyx Pharma
Ultragenyx to Host Conference Call for Second Quarter 2025 Financial Results and Corporate Update
GlobeNewswire Inc.
Jul 30, 2025 12:30 PM GMT
NOVATO, Calif., July 30, 2025 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE), a biopharmaceutical company focused on the development and commercialization of novel products for serious rare and ultra-rare genetic diseases, today